Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- PSA Velocity Does Not Improve Prostate Cancer Detection
(Posted: 04/13/2011) - A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute.
- Certain Physicians Are More Likely to Refer Patients to Clinical Trials
(Posted: 04/08/2011) - According to a survey-based study of more than 1,500 physicians treating patients with lung or colorectal cancer published online February 11, 2011 in the Journal of the National Cancer Institute, medical oncologists were the most likely and surgeons the least likely to refer patients to, or enroll them in, clinical trials.
- Targeted Therapies May Be Effective Against Rare Pancreatic Cancer
(Posted: 04/08/2011) - In two phase III clinical trials published February 9, 2011, in the New England Journal of Medicine (NEJM), the targeted therapies sunitinib and everolimus improved outcomes for patients with pancreatic neuroendocrine tumors.
- Some Women May Not Need More Extensive Lymph Node Surgery for Breast Cancer
(Posted: 03/31/2011) - Results from a randomized clinical trial published February 9, 2011, in the Journal of the American Medical Association demonstrate that axillary lymph node dissection provided no additional survival benefit when compared with sentinel lymph node biopsy in women with small breast tumors and minimal lymph node metastasis who were treated with lumpectomy, whole-breast radiotherapy, and adjuvant systemic therapy.
- When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.